Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1951 +/- pembrolizumab in advanced solid tumors
NCT03799003Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Jan 2019
- Primary completion
- Jul 2023
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 4
01
Overview
Phase 1, open-label trial of asp1951 in solid tumor, squamous cell carcinoma of the head and neck (HNSCC), non-small cell lung cancer (NSCLC) and 3 more (3 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicity at 5 years, Adverse Events at 5 years and 5 more. Started Jan 2019; status: terminated.
02
Drugs
asp1951
03
Conditions
solid tumorsquamous cell carcinoma of the head and neck (HNSCC)non-small cell lung cancer (NSCLC)Cervical Cancer (CC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03799003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799003.